GNB2 and glioma: There was no significant difference between GNB2 subgroup and GNB3 subgroup in the sensitivity to methotrexate, which was used for CSF injection in glioma patients with spinal dissemination, and both were higher than that in GNB5 subgroup (Figure 3O).